No Detail Found!

Network pharmacology analysis of “Ling Gui Zhu Gan Decoction” in the treatment of obesity-associated non-alcoholic fatty liver disease

Author(s)
Xiao Yang Chen Department of Traditional Chinese Medicine, Yongjia People's Hospital,Wenzhou, Zhejiang,China
Chen Fei Huang Department of Traditional Chinese Medicine, Yongjia People's Hospital,Wenzhou, Zhejiang,China
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a prevalent liver condition closely associated with obesity, affecting nearly one billion adults worldwide. "Ling Gui Zhu Gan Decoction," a traditional Chinese medicine composed of Poria, Cinnamon Twig, Atractylodes macrocephala and Licorice, has demonstrated clinical efficacy in treating obesityassociated NAFLD. The active components and targets of "Ling Gui Zhu Gan Decoction" were identified using the TCMSP, PubChem and Swiss Target Prediction databases. Disease targets for NAFLD and obesity were retrieved from GeneCards. A protein-protein interaction (PPI) network was constructed, followed by functional enrichment analyses (GO and KEGG). Finally, a drug-disease-pathway network was established. The study identified 108 therapeutic targets for "Ling Gui Zhu Gan Decoction." Key components such as trametenolic acid and cerevisterol, along with targets like PTPN1, ESR1 and EGFR, were implicated in pathways including HIF-1, NF-?B and AMPK signaling. Molecular docking further confirmed that PTPN1 can stably bind with trametenolic acid and cerevisterol. These findings suggest that "Ling Gui Zhu Gan Decoction" exerts its effects through multiple targets and pathways. Network pharmacology elucidates the potential of "Ling Gui Zhu Gan Decoction" in treating obesity-associated NAFLD through multi-target and multi-pathway mechanisms, offering an alternative therapeutic option for this condition.
Publication Details
Page(s) 1011-1021
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 38, Issue: 3, Year: 2025

Request the full text from PASTIC

Keywords
Obesity, Metabolism, alcoholic liver disease, Ling Gui Zhu Gan decoction
References
Alam MB,Chowdhury NS,Sohrab MH,Rana MS,Hasan CM,Lee SH .2020 .Cerevisterol alleviates Inflammation via suppression of MAPK/NF-κB/AP-1 and activation of the Nrf2/HO-1 signaling cascade. Biomolecules, 10(2) : 199.
Anstee QM,Castera L,Loomba R .2022 .Impact of non-invasive biomarkers on hepatology practice: Past, present and future. J. Hepatol., 76(6) : 1362-1378.
Cotter TG,Rinella M .2020 .The state of the disease. Gastroenterology, 158(7) : 1851-1864.
Chen CX,Zhang W,Qu S,Xia F,Zhu Y,Chen B Y .2023 .A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways. Cell Commun, 21(1) : 287.
Chen J,Feng S,Li L,Qiu S,Jin Y,Sun Y Y .2022 .Protective role of trametenolic acid B against sevoflurane-induced cognitive impairments by its different regulatory modalities of mir-329-3p in neurons and microglia. Mol. Med, 28(1) : 77.
Duan Q,Tian L,Feng J,Ping X,Li L,Yaigoub H,Li R,Li Y .2022 .Trametenolic acid ameliorates the progression of diabetic nephropathy in db/db mice via Nrf2/HO-1 and NF-κB-mediated pathways. J. Immunol. Res., : 6151847.
Dufour JF,Anstee QM,Bugianesi E,Harrison S,Loomba R,Paradis V,Tilg H,Wong VW,Zelber-Sagi S .2022 .Current therapies and new developments in NASH. , 71(10) : 2123-2134.
Eberhardt J,Santos-Martins D,Tillack AF,Forli S AF .2021 .New docking methods, expanded force field and python bindings. J. Chem, 61(8) : 3891-3898.
Filali-Mouncef Y,Hunter C,Roccio F,Zagkou S,Dupont N,Primard C,Proikas-Cezanne T,Reggiori F .2022 .The ménage à trois of autophagy, lipid droplets and liver disease. Autophagy, 18(1) : 50-72.
Fan L,Niu H,Zhao L,Yao R,He X,Lu B,Pang Z B .2022 .Purendan alleviates non-alcoholic fatty liver disease in aged type 2 diabetic rats via regulating mTOR/S6K1/SREBP-1c signaling pathway. Biomed, 148 : 112697.
Guo X,Yin X,Liu Z,Wang J .2022 .Non-Alcoholic Fatty Liver Disease (NAFLD) Pathogenesis and natural products for prevention and treatment. Int. J. Mol. Sci, 23(24) : 15489.
Gong W,Chen X,Shi T,Shao X,An X,Qin J,Chen X,Jiang Q,Guo B .2021 .Network pharmacologybased strategy for the investigation of the antiosteoporosis effects and underlying mechanism of Zhuangguguanjie formulation. Front Pharmacol, 12 : 727808.
Hardesty JE,Wahlang B,Prough RA,Head KZ,Wilkey D,Merchant M,Shi H,Jin J,Cave MC .2021 .Effect of epidermal growth factor treatment and polychlorinated biphenyl exposure in a dietary-exposure mouse model of steatohepatitis. Environ. Health Persp., 129(3) : 37010.
Huang J,Lin Z,Wang Y,Ding X,Zhang B .2023 .Wuling san based on network pharmacology and in vivo evidence against hyperuricemia via improving oxidative stress and inhibiting inflammation. Drug Des. Dev, 17 : 675-690.
Hsieh WT,Hsu MH,Lin WJ,Xiao YC,Lyu PC,Liu YC,Lin WY,Kuo YH,Chung JG,- JG .2021 .-ol Interferes with LPS Docking to LBP, CD14 and TLR4/MD-2 Co-receptors to attenuate the nfκb inflammatory pathway in vitro and drosophila. Int. J. Mol. Sci, 22(12) : 6511.
Huang YP,Chen DR,Lin WJ,Lin YH,Chen JY,Kuo YH,Chung JG,Hsia TC,Hsieh WT,- WT .2021 .-ol attenuates inflammatory responses via inhibiting mapk/ap-1 induced IL-6/JAK/STAT pathways and activating Nrf2/HO-1 signaling in LPS-stimulated macrophage-like cells. Antioxidants, 10(9) : 1430.
Ito Y,Sun R,Yagimuma H,Taki K,Mizoguchi A,Kobayashi T,Sugiyama M,Onoue T,Tsunekawa T,Takagi H,Hagiwara D,Iwama S,Suga H,Konishi H,Kiyama H,Arima H,Banno R H .2022 .Protein tyrosine phosphatase 1b deficiency improves glucose homeostasis in type 1 diabetes treated with leptin. Diabetes., 71(9) : 1902-1914.
Juanola O,Martínez-López S,Francés R,GómezHurtado I .2021 .Non-alcoholic fatty liver disease: metabolic, genetic, epigenetic and environmental risk factors. Int. J. Environ. Res. Pub. He., 18(10) : 5227.
Johanns M,Corbet C,Jacobs R,Drappier M,Bommer GT,Herinckx G,Vertommen D,Tajeddine N,Young D,Messens J,Feron O,Steinberg GR,Hue L,Rider MH .2022 .Inhibition of basal and glucagon-induced hepatic glucose production by 991 and other pharmacological AMPK activators. Biochem. J., 479(12) : 1317-1336.
Loomba R,Friedman SL,Shulman GI .2021 .Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell., 184(10) : 2537-2564.
Niu B,Xie X,Xiong X,Jiang J .2022 .Network pharmacology-based analysis of the anti-hyperglycemic active ingredients of roselle and experimental validation. Comput. Biol. Med, 141 : 104636.
Portincasa P and Baffy G .2024 .Metabolic dysfunctionassociated steatotic liver disease: Evolution of the final terminology. Eur. J. Intern. Med, 124 : 35-39.
Pansa CC,Molica LR,Moraes KCM .2023 .Nonalcoholic fatty liver disease establishment and progression: genetics and epigenetics as relevant modulators of the pathology. Scand. J. Gastroentero., 58(5) : 521-533.
Pinter M,Pinato DJ,Ramadori P,Heikenwalder M .2023 .NASH and hepatocellular carcinoma: immunology and immunotherapy. Clin. Cancer Res., 29(3) : 513-520.
Pafili K and Roden M .2021 .Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. Mol. Metab, 50 : 101122.
Rong L,Zou J,Ran W,Qi X,Chen Y,Cui H,Guo J .2023 .Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front Endocrinol., 13 : 1087260.
Rinella ME,Neuschwander-Tetri BA,Siddiqui MS,Abdelmalek MF,Caldwell S,Barb D,Kleiner DE,Loomba R .2023 .AASLD Practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. J. Hepatol., 77(5) : 1797-1835.
Shi S,Chen Y,Luo Z,Nie G,Dai Y .2023 .Role of oxidative stress and inflammation-related signaling pathways in doxorubicin-induced cardiomyopathy. Cell Commun, 21(1) : 61.
Song Q,Zhang X,Liu W,Wei H,Liang W,Zhou Y,Ding Y,Ji F,Ho-Kwan Cheung A,Wong N,Yu J .2023 .Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma. J. Hepatol., 79(6) : 1352-1365.
Teng ML,Ng CH,Huang DQ,Chan KE,Tan DJ,Lim WH,Yang JD,Tan E,Muthiah MD .2023 .Global incidence and prevalence of nonalcoholic fatty liver disease. Clin. Mol. Hepatol, 29(Suppl) : S32-S42.
Yan T,Yan N,Wang P,Xia Y,Hao H,Wang G,Gonzalez FJ .2020 .Herbal drug discovery for the treatment of nonalcoholic fatty liver disease. Acta. Pharm. Sin. B., 10(1) : 3-18.
Xu M,Xue H,Kong L,Lin L,Zheng G .2023 .Smilax china L. polyphenols improves insulin resistance and obesity in high-fat diet-induced mice through IRS/AKTAMPK and NF-κB signaling pathways. Plant Food Hum. Nutr, 78(2) : 299-306.
Younossi ZM,Golabi P,Paik JM,Henry A,Van Dongen C and Henry L A .2023 .The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review. J. Hepatol., 77(4) : 1335-1347.
Zhang X,Mou Y,Aribas E,Amiri M,Nano J,Bramer WM,Kavousi M,de Knegt RJ,Asllanaj E,Ghanbari M .2022 .Associations of sex steroids and sex hormonebinding globulin with non-alcoholic fatty liver disease: A population-based study and meta-analysis. Genes., 13(6) : 966.
Zhang Y,Murugesan P,Huang K,Cai H K .2020 .NADPH oxidases and oxidase crosstalk in cardiovascular diseases: Novel therapeutic targets. Nature reviews. Cardiology., 17(3) : 170-194.
Zhou Z,Zhang J,You L,Wang T,Wang K,Wang L,Kong X,Gao Y,Sun X Y .2022 .Application of herbs and active ingredients ameliorate non-alcoholic fatty liver disease under the guidance of traditional Chinese medicine. Front Endocrinol., 13 : 1000727.
Zhu K,Guo Y,Zhao C,Kang S,Li J,Wang J,Tang Z,Lin B,Li W .2021 .Etiology exploration of nonalcoholic fatty liver disease from traditional chinese medicine constitution perspective: A cross-sectional study. Front Public Health.,, 9 : 635818.
0

Citations

0

Downloads

99

Views